J&J, AZ and the University of Oxford, alongside outside scientists, are planning to conduct early research into the potential of modifications to their vaccines to reduce or remove the risk of rare but serious blood clots associated with the jabs, The Wall Street Journal (WSJ) has reported.
While a J&J spokesman said the company supports “continued research and analysis”, AZ said it is ““actively working with the regulators and scientific community to understand these extremely rare blood-clotting events, including information to drive early diagnosis and intervention, and appropriate treatment”, as quoted by WSJ.
